Sixty @entity1 with chronic @entity615 or lumboischialgia with exacerbation for at least 1 month were included in the study. A main group consisted of 40 @entity1 and a control group of 20 @entity1 . All @entity1 took @entity3522 in dosage 100 mg per day from the 1st day. Versatis was prescribed to @entity1 of the main group from the 6th day. One-three plates were applied to the most painful spine areas and low extremities for 12 h during 5 days. To assess treatment efficacy, scales for measuring @entity615 , @entity5525 , @entity9 (NPS) as well as the Global Impression scale (CGI) and quality of life (EQ-5D) were used. A significant clinical effect was observed in 63% of @entity1 of the main group: the additional reduction of @entity158 by about a quarter, decrease of @entity5525 intensity, improvement of functional activity - spinal flexion-extension, ability to standing and quality of life. The NPS revealed that the use of versatis resulted in the significant decrease of "neuropathic" characteristics of @entity158 ; this effect remained after the end of treatment. The anesthetic effect of plates emerged in 1,2+/-1,1h after application, reached the maximum after 3,8+/-2,0 h, and continued during 4,7+/-2,2 h after removing the plates from the skin. The safety of @entity3303 -coated plates was observed.

[The use of @entity3303 -coated plates (versatis) in the treatment of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5525 :: ('MESH:C538664', 'Disease') :: ['vertebral syndrome'] @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac'] @entity615 :: ('MESH:D001416', 'Disease') :: ['vertebrogenic lumbalgia', 'back pain'] @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']
@entity615 :: (MESH:D001416,Disease) :: ['back pain']
